Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

• Main Authors: Marianne Berdugo (Author), Kimberley Delaunay (Author), Cécile Lebon (Author), Marie-Christine Naud (Author), Lolita Radet (Author), Léa Zennaro (Author), Emilie Picard (Author), Alejandra Daruich (Author), Jacques Beltrand (Author), Elsa Kermorvant-Duchemin (Author), Michel Polak (Author), Patricia Crisanti (Author), Francine F. Behar-Cohen (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...